Unresectable stage III disease according to the AJCC 8th edition;
Negative for driver gene alterations;
Considered suitable for definitive cCRT by MDT discussion or investigator judgment;
ECOG performance status 0-1;
Presence of a clearly delineable pulmonary primary lesion allowing centrally confined priming treatment planning;
Adequate major organ function as required by the study;
Willingness to participate and provision of written informed consent.
You may not be if
Presence of distant metastasis;
Positive driver gene alterations;
Prior definitive thoracic radiotherapy or prior systemic antitumor treatment for the current disease;
Active autoimmune disease or need for long-term systemic immunosuppressive therapy;
Active interstitial lung disease, prior severe radiation pneumonitis, or immune-related pneumonitis;
Special primary tumor location such that safety constraints for centrally confined priming radiotherapy cannot be met;
Primary lesion immediately adjacent to the main bronchus, carina, major vessels, or esophagus, such that the investigator judges the lead-in intervention to be excessively risky;
Pregnancy or lactation;
Any other condition that, in the opinion of the investigator, makes the patient unsuitable for this study.
Clareo Health | Centrally Confined 8Gy/1f to Tumor Core Followed by Concurrent Chemoradiotherapy for Unresectable Stage III NSCLC
